Increased Angiotensin II Type 1 Receptor Expression in Hypercholesterolemic Atherosclerosis in Rabbits

From the Departments of Medicine (B.C.Y., J.L.M.), Physiology (M.I.P., D.M., H.M., L.S., J.L.M.), and Pediatrics (P.M.), University of Florida, College of Medicine, and the VA Medical Center (J.L.M.), Gainesville, Fla.

Correspondence to J.L. Mehta, MD, PhD, Department of Medicine, University of Florida College of Medicine, 1600 Archer Rd, PO Box 100277 JHMHC, Gainesville, FL 32610. E-mail jmehta{at}ufl.edu

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Abstract—Angiotensin II (Ang II) promotes vascular smooth muscle growth and may be involved in the initiation and progression of atherosclerosis. To examine whether Ang II receptor expression in vascular tissues is altered in atherosclerosis, male New Zealand White rabbits were fed a high-cholesterol diet (1% cholesterol+4% coconut oil mixed with regular chow; hypercholesterolemic group, n=12) or regular chow (control group, n=8) for 10 weeks. At the end of this period, the serum cholesterol level in the rabbits fed the high-cholesterol diet was higher than that in the control group (3616±144 versus 30±1 mg/dL, P<0.001). There was no atherosclerosis in the aortas of the control group, whereas 51±6% of the aorta was covered with atherosclerosis in the hypercholesterolemic group. Total Ang II receptor expression in the atherosclerotic aortic tissues was increased 5-fold in the hypercholesterolemic rabbits (292±28 versus 51±32 fmol/mg tissue, mean±SE, P<0.001), and the increased Ang II receptor expression was entirely due to enhanced Ang II type 1 (AT₁) receptor expression (289±38 versus 38±18 fmol/mg, P<0.001), as Ang II type 2 receptor expression was unaltered (7±5 versus 3±2 fmol/mg, P=NS). AT₁ receptors were localized primarily in the media and to some extent in the intima of the atherosclerotic aorta, as determined by immunohistochemistry with specific monoclonal and polyclonal AT₁ receptor antibodies. Increased synthesis of AT₁ receptor mRNA in atherosclerotic tissues was confirmed by reverse transcription–polymerase chain reaction. To evaluate the functional significance of increased AT₁ receptor expression, the constrictor response of aortic rings to Ang II was examined and found to be markedly enhanced in atherosclerotic aortic rings (P<0.01 versus control aortic rings). The endothelium-dependent relaxation of aortic rings from hypercholesterolemic rabbits was markedly attenuated (P<0.001). This study shows that hypercholesterolemia in rabbits results in atherosclerosis, loss of endothelium-dependent relaxation, and increased Ang II receptor (entirely AT₁ receptor) expression in aortic tissues, which may result in altered vasoreactivity.

Key Words: aorta • atherosclerosis • angiotensin II • endothelium • hypercholesterolemia

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Angiotensin II (Ang II) is a potent vasoactive peptide that produces systemic and local vasoconstriction.¹ Relatively recent studies indicate that Ang II also has direct cellular effects on the pathobiology of vascular disease through growth-promoting activity. At least 2 distinct Ang II receptor subtypes, type 1 and type 2 (AT₁ and AT₂, respectively), have been identified.¹ Binding of Ang II to its target AT₁ in vascular tissues activates phospholipase C; raises intracellular calcium² ; activates nuclear elements that affect gene expression; and stimulates protein synthesis, mitogenesis, or hypertrophy.^{3 4 5} These phenomena are observed in quiescent vascular smooth muscle cells incubated with Ang II.³ In vascular smooth muscle cells, Ang II has been shown to activate fibroblast growth factor, platelet-derived growth factor, and transforming growth factor-ß1.^{4 5} Ang II also mediates vascular smooth muscle cell growth and migration, monocyte/macrophage activation, and platelet activation and stimulates atherogenesis.⁶

Rakugi et al⁷ demonstrated induction of the angiotensin-converting enzyme (ACE) in the neointima of injured blood vessels and speculated on its possible role in restenosis after angioplasty. Viswanathan et al⁸ described increased Ang II receptor expression in the neointima after vascular injury, which would facilitate the action of Ang II. ACE has also been found in vascular smooth muscle cells in intimal lesions and in macrophages and vascular smooth muscle cells in the fibroproliferative lesion of human atherosclerotic plaques from atherectomy, surgical, and postmortem specimens.⁶ It is, therefore, possible that excessive Ang II synthesis, activity, or receptor expression contributes to the initiation or progression of atherosclerosis.

Abnormally high serum cholesterol levels are thought to be an important pathogenic factor in atherogenesis.⁹ An inherited form of hypercholesterolemia leads to early atherosclerosis in rabbits.¹⁰ Feeding of a high-cholesterol diet to rabbits often results in hypercholesterolemia and atherosclerosis.¹¹ Although the extent of atherosclerosis in different blood vessels of rabbits fed a high-cholesterol diet varies significantly, this model has been used extensively to study pathogenetic aspects of atherosclerosis and its modulation by various agents.^{11 12 13} The current study was designed to examine Ang II receptor expression in vascular tissues and its relationship with vasoreactivity and atherogenesis in a rabbit model of atherosclerosis induced by feeding of a high-cholesterol diet.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Hypercholesterolemic Rabbits
Male New Zealand White rabbits (1 kg weight) were housed individually under temperature-controlled conditions. During the 2-week period of adaptation, the rabbits were fed standard rabbit chow and water ad libitum. Food intake was assessed on a daily basis. After stabilization, the rabbits were randomly assigned to 1 of the 2 regimens for 10 weeks: (1) standard rabbit chow (control group, n=8) or (2) cholesterol-enriched rabbit chow (1% cholesterol plus 4% coconut oil mixed with regular chow; high cholesterol–diet group, n=12). Only male rabbits were used to avoid the variability secondary to sex differences in this experimental model. A rabbit chow containing 1% cholesterol and 4% coconut oil diet was chosen because other investigators have demonstrated that when given for a period of 10 to 12 weeks, it results in marked elevation in serum cholesterol and induction of diffuse, aortic atherosclerosis.^{11 12 13}

At the end of the 10-week dietary intervention, food was withdrawn for 12 hours, and the rabbits were weighed and then anesthetized with intravenous sodium pentobarbital (50 mg/kg). Venous blood samples were obtained for measurement of serum cholesterol, and aortas were excised for examination of atherosclerotic area (aorta), Ang II receptor binding, and determination of vasoreactivity. The total RNA was extracted from aortas from treated and untreated animals and analyzed by reverse transcription– polymerase chain reaction (RT-PCR). The study was approved by the appropriate animal research committees of the University of Florida and complied with the American Physiological Society guidelines.

Determination of Serum Cholesterol
Serum was analyzed for total cholesterol by an automatic analyzer at a commercial laboratory (Doctors' Laboratory, Valdosta, Ga).

Determination of the Extent of Atherosclerosis
After dissection, the entire aorta (except the ascending part) was removed, opened longitudinally, and prepared for detection and quantification of areas of sudanophilia as directed by Holman et al.¹⁴ The aortic strips were immersed in 10% buffered formalin solution for 24 hours and then rinsed briefly in 70% alcohol. The tissues was immersed in Herxheimer's solution that contained 5 g Sudan IV, 500 mL of 70% ethyl alcohol, and 500 mL acetone at room temperature for 15 minutes. The aortas were then transferred to 80% alcohol for 20 minutes, washed in running water for 1 hour, and then mounted and photographed. Aortic atherosclerosis was determined by planimetry of the distribution of sudanophilia in the photographs and expressed as percent of aortic area.

Determination of Ang II Receptor Binding by Autoradiography
Aortic Ang II receptor expression was determined as Ang II receptor binding by autoradiography. Ascending aortas were frozen on dry ice. Multiple 20-µm-thick transverse sections were cut at -20°C, mounted onto chrome-alum-gelatin–coated slides, and incubated with 250 to 300 pmol/L ¹²⁵I-Sar-Ile-Ang II for 2 hours in 10 mmol/L sodium biphosphate buffer or buffer containing 10 µmol/L of the Ang II receptor blocker [Sar¹, Val⁵ , Ala⁸]-Ang II, 10 µmol/L of the AT₂ receptor blocker PD123,177, or 10 µmol/L of the AT₁ blocker losartan. The sections were washed in buffer and dried. Autoradiograms were generated by apposition of slide-mounted tissue sections with x-ray film (Hyperfilm-³H, Amersham) for 3 weeks. Densitometric analysis of the autoradiographs was carried out with Image Systems equipment (MCID M1 software with Tk/M1 turnkey system with an 80486, 33-MHz computer; Imaging Research, Inc).^{15 16 17}

Determination of Vasoreactivity
Thoracic aortic segments were isolated and placed in 95% O₂–5% CO₂–saturated Krebs-Ringer buffer (composition in mmol/L: NaCl 118, KCl 4.7, CaCl₂ 2.5, KH₂PO₄ 1.2, MgCl₂ 1.2, NaHCO₃ 12.5, glucose 11.1, and disodium EDTA 0.01, pH 7.4). The vascular tissues were cleaned of visible connective and fatty tissues and cut in 2- to 3-mm rings. The rings were mounted onto wire stirrups, suspended in tissue baths filled with Krebs-Ringer buffer at 37°C, and connected to force transducers (Grass Instruments) to record changes in isometric force. The rings were then stretched to and maintained at a preload of 2 g and allowed to equilibrate for 2 hours. During the equilibration period, the buffer was changed every 30 minutes and continuously bubbled with 95% O₂ and 5% CO₂. After equilibration, some aortic rings were exposed to cumulative concentrations of norepinephrine (NE, 10^-10 to 10^-5 mol/L) or Ang II (10^-10 to 10^-6 mol/L) to determine the contractile response. Other aortic rings were contracted with NE (10^-7 mol/L) to obtain 60% to 70% of maximal contraction and then exposed to the endothelium-dependent vasorelaxant acetylcholine (ACh, 10^-10 to 10^-6 mol/L). The relaxation was expressed as percent change from preexisting (before addition of vasorelaxant) tone.¹⁸

Immunohistochemical Localization of AT₁ Receptors
Multiple 8-µm-thick transverse sections of aorta were made and fixed in ice-cold acetone for 5 minutes. After preincubation with 0.1% BSA, 10% normal goat serum, and 0.5% Triton X for 20 minutes followed by a rinse with Tris-buffered saline (TBS), the sections were incubated with a monoclonal antibody against rat AT₁ receptors (a gift from Professor G.P. Vinson, London, England)¹⁹ diluted 1:10 in TBS–1% BSA (pH 7.4) overnight at 4°C. After being rinsed with TBS, a biotin-streptavidin detection system was used with diaminobenzidine as the chromogen, as described elsewhere.²⁰ In brief, slides were washed twice with TBS and incubated with the linking reagent (biotinylated horse anti-mouse IgG) for 20 minutes at room temperature. After being rinsed in TBS, the slides were incubated with peroxidase-conjugated streptavidin label for 20 minutes at room temperature. The section were again rinsed in TBS and incubated with diaminobenzidine in the dark for 10 minutes. Mouse serum applied instead of the primary antibody was used as a negative control.²⁰ In some experiments, immunohistochemical localization of AT₁ receptors was conducted by using a rat polyclonal antibody produced by autoimmunization of rats with the AT₁ receptor and detected by an FITC horse anti-mouse IgG.²¹

AT₁ Receptor mRNA Expression by RT-PCR
Total RNA was isolated from aortas of control and high cholesterol–diet-fed rabbits by the guanidinium thiocyanate–phenol-chloroform method.²² The quality of isolated RNA was checked by gel electrophoresis. For this purpose 2 µg of total RNA was denatured in a 50% formamide and 20% formaldehyde mixture for 10 minutes at 65°C. Denatured RNA was fractionated by gel electrophoresis on a 1% agarose gel containing 10% formaldehyde and examined under UV light after being stained with ethidium bromide. Five micrograms of the total RNA was digested with DNase I (RNase free) for 10 minutes at 37°C in the presence of 5 U of RNase inhibitor. After heat inactivation of DNase, RNA was reverse-transcribed for 50 minutes at 42°C with SuperScript II reverse transcriptase (Gibco-BRL) with oligo(dT) as the primer (Promega) in a 20-µL volume reaction mixture. The reaction was stopped by heating the samples for 15 minutes at 70°C. Ten percent of the single-stranded cDNA was used a template for amplification in the PCR with the use of Taq polymerase (Gibco-BRL). Primers were designed on the basis of the Ang II AT₁ receptor sequence cloned from the rabbit kidney cortex.²³ The sense primer sequence was 5'-TTTGGGAACAGCTTGGCGGT-3'; reverse primer was 5'-GCCAGCCAGCAGCCAAATAA-3'. After 5 minutes at 94°C, amplification was performed at 94°C for 45 seconds, 55°C for 45 seconds, and 68°C for 60 seconds for 40 cycles with a final incubation at 68°C for 7 minutes. Eight microliters of the PCR mixture was separated on a 1% agarose gel stained with ethidium bromide.

Statistical Analysis
All data are expressed as mean±SEM. Means of different groups were compared by ANOVA followed by Newman-Keuls test for paired and unpaired observations. A P value <0.05 was considered significant.

	Results

Top Abstract Introduction Methods Results Discussion References

 
High-Cholesterol Diet, Hypercholesterolemia, and Atherosclerosis
In the high cholesterol–diet group, 2 of 12 rabbits died of a lung infection at week 2. There were no deaths in the control group. At the end of the 10-week period, body weight was similar in the control (2.95±0.05 kg, n=8) and high cholesterol–diet (2.74±0.12 kg, n=10) groups. Serum cholesterol level in the high cholesterol–diet group was markedly higher than in the control group (3616±144 versus 30±1 mg/dL, P<0.001). The control group showed no atherosclerosis, whereas the high cholesterol–diet group showed 51±6% of the aorta covered with atherosclerosis (P<0.01 versus control).

Reactivity of Aortic Rings in Response to NE, Ang II, and ACh
The contractile response of aortic rings to Ang II and NE is shown in Figure 1. Aortic ring contraction in response to Ang II was markedly increased in all atherosclerotic rabbits compared with control rabbits (P<0.01). The greater contraction was seen in rings from all rabbits fed the high-cholesterol diet. The contractile response of aortic rings to NE was also greater in rings from hypercholesterolemic rabbits than in those from normal-cholesterol rabbits (P<0.01).

View larger version (26K): [in this window] [in a new window]   Figure 1. Contractile responses of rabbit aortic rings to NE and Ang II and relaxant responses of rabbit aortic rings to ACh. Contractile response of aortic rings was increased in hypercholesterolemic rabbits compared with control rabbits (P<0.01). Relaxant response of aortic rings to ACh was decreased in hypercholesterolemic rabbits (both P<0.01 versus control rabbits). Each data point is mean (±SEM) of 3 to 10 observations in different rabbits.

On exposure to the endothelium-dependent vasorelaxant ACh, aortic rings from control rabbits exhibited a typical concentration-dependent relaxation. In contrast, aortic rings from 4 hypercholesterolemic rabbits did not show any relaxation, and rings from the remaining hypercholesterolemic rabbits exhibited only modest relaxation in response to low concentration of ACh (10^-7 mol/L) and a modest degree of contraction in response to a higher concentration of ACh (10^-6 mol/L), a phenomenon not observed in any of the rabbits fed regular chow. The rightward shift in the ACh dose-response curve was highly significant (P<0.001). These data on the relaxant reactivity of aortic rings in response to ACh are also summarized in Figure 1.

Ang II Receptor Expression in Aortic Tissues by Autoradiography
Ang II receptor expression in aortic tissues was determined by autoradiography. Total Ang II receptor expression in the aortic tissues was several-fold higher in the hypercholesterolemic rabbits than in the control group (P<0.001). The increase in Ang II receptor expression was entirely due to an increase in AT₁ expression in the hypercholesterolemic rabbits (P<0.001), as AT₂ expression in the aortic rings was similar in the 2 groups. A representative autoradiogram is shown in Figure 2, and data from control and hypercholesterolemic rabbits are summarized in Figure 3. Although the precise localization of increased AT₁ receptor density could not be discerned from the autoradiographs, expression appeared to be predominantly in the media and intima.

View larger version (60K): [in this window] [in a new window]   Figure 2. Representative autoradiographs of aortic rings from control and hypercholesterolemic rabbits. Note marked increase in total Ang II receptor expression in hypercholesterolemic rabbit aortic segment. Increase in Ang II receptor expression was entirely due to an increase in AT1 receptor expression, as AT2 receptor expression was unaffected.

View larger version (15K): [in this window] [in a new window]   Figure 3. Summary of data on Ang II receptor binding (which represents Ang II receptor expression) in aortic and myocardial tissues. Total Ang II receptor binding and AT1 binding in aortic tissues were markedly higher in the hypercholesterolemic group than in the control group of rabbits (P<0.01). AT2 binding in aortic tissues was similar in the 2 groups.

Immunohistochemical Localization of AT₁ Receptors
AT₁ receptor expression was localized in aortic tissues from hypercholesterolemic rabbits as well as from the control group by immunohistochemical staining. With a monoclonal antibody, AT₁ receptor expression was predominantly in the smooth muscle layers, although there was immunopositivity in the intima as well. AT₁ receptors were present in both the cytoplasm and cell membranes. Representative photomicrographs showing the distribution of immunopositivity are shown in Figure 4. With the use of a polyclonal antibody, expression of AT₁ receptors was heavily concentrated in the media and to a much smaller extent in the endothelial lining (Figure 5). Although the immunocytochemical technique is not quantitative, the higher density of AT₁-like receptors in the hypercholesterolemic aortas was striking.

View larger version (106K): [in this window] [in a new window]   Figure 4. Immunohistochemistry of aortic tissues from control (left) and high cholesterol–diet-fed rabbits (right) by use of a specific AT1 monoclonal antibody.19 Note that AT1 expression is mostly in the medial layers, although there is immunopositivity in the intima as well as subintimal plaque region. Negative control (without use of primary antibody) sections are shown in lower panels (Original magnification x200). E in upper panels indicates endothelial lining.

View larger version (121K): [in this window] [in a new window]   Figure 5. Immunohistochemistry of aorta from a high cholesterol–diet-fed rabbit by use of a polyclonal antibody against AT1 receptors raised in rat.21 Note that AT1 receptors are primarily localized in the media.

Evidence for Increased AT₁ mRNA by RT-PCR
Using AT₁-specific primers, we amplified an expected size band of 341 bp (Figure 6). The aortic AT₁ receptor mRNA level of the high-cholesterol group was markedly increased compared with the control group, wherein AT₁ receptor mRNA was almost undetectable (Figure 6).

View larger version (30K): [in this window] [in a new window]   Figure 6. RT-PCR amplification of AT1 receptor mRNA in rabbit aorta. Five micrograms of total RNA was subjected to RT-PCR as described in Methods. Amplified fragment of AT1 receptor is 341 bp. Control indicates plasmid containing AT1 cDNA, amplified in parallel with rabbit samples; control, rabbits fed with standard diet; and CH, rabbits fed with high-cholesterol diet.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
Supplementation of the diet with cholesterol resulted in marked hypercholesterolemia, atherosclerosis, and increased Ang II receptor expression in the aortic tissues in this study. The enhanced Ang II receptor expression was almost entirely due to an increase in AT₁ expression, which may have significant implications in atherogenesis and its treatment. The biological significance of enhanced AT₁ receptor expression was evident from increased constrictor response of aortic rings to Ang II.

Abnormally high serum cholesterol levels are thought to be an important pathogenic factor in atherosclerosis.¹⁰ There is a positive correlation between total serum cholesterol and coronary mortality rates.²⁴ In addition, there is strong clinical evidence that lowering the total serum cholesterol level decreases the incidence of cardiac events in patients with preexisting coronary artery disease²⁵ and others at high risk of developing coronary artery disease²⁶ and retards progression of symptomatic atherosclerosis.²⁷ In the current study, feeding of a high-cholesterol diet to rabbits for 10 weeks resulted in marked hypercholesterolemia and development of atherosclerosis, which is consistent with several previous reports.^{12 13 14} These findings confirm an important role for hypercholesterolemia in atherogenesis.

Endothelium-derived relaxing factor (EDRF), most likely NO or a closely related compound, relaxes vascular smooth muscle and inhibits oxidative modification of LDL, cell adhesion, vascular smooth muscle proliferation, and platelet aggregation.^{28 29 30 31} Via release of EDRF/NO and prostacyclin, the vascular endothelium plays an important role in preventing the evolution of atherosclerosis.³² Several investigators^{33 34 35} have documented the involvement of endothelial dysfunction in atherosclerosis. The impaired EDRF-dependent vasodilatation in hypercholesterolemia and atherosclerosis has been documented in both rabbit³⁴ and human³⁵ arteries. The current study confirms that a high-cholesterol diet results in impaired relaxation of arterial tissues in response to the endothelium-dependent vasorelaxant ACh. The decreased relaxation in response to ACh implies a decrease in NO synthesis or an increase in its degradation.

An interesting and novel observation described in this report pertains to enhanced contraction of aortic tissues from hypercholesterolemic rabbits in response to Ang II. The contractile response to Ang II was enhanced in hypercholesterolemic rabbits compared with the controls. The increased contractile response of aortic rings paralleled the increase in Ang II receptor expression. We found that aortic ring contractile response to NE was also increased in hypercholesterolemic rabbits. It is possible that the greater contractile response to Ang II and NE is a manifestation of attenuated NO activity in these rings. It is also possible that hypercholesterolemia per se enhances contractile responses to multiple agonists, such as NE and thrombin.³³ Hof et al³⁶ have also shown an enhanced contractile response to Ang II as well as to NE in atherosclerosis. A recent study has shown that Ang II induces transcription and expression of ₁-adrenergic receptors in vascular smooth muscle cells.³⁷ This mechanism may also underlie the greater contractile response to NE in atherosclerosis. Dusting et al,³⁸ however, could not find any difference in vasoconstrictor response to Ang II in control and hypercholesterolemic rabbits, but these investigators did not report on the extent of atherosclerosis and Ang II receptor expression. The variable response to vasoconstrictors may relate to differences in Ang II receptor expression and the extent of atherosclerosis in different blood vessels. It is possible that extensive plaque formation and distorted smooth muscle architecture in the atherosclerotic aorta leads to altered vasoconstriction. Notably, treatment with ACE inhibitors has been shown to alter vasoconstriction in an experimental setting and to decrease the facilitatory influence of Ang II on sympathetic stimulation.³⁹ Because it is the AT₁ receptor activation that results in vasoconstriction in response to Ang II, we believe that the upregulation of AT₁ receptor number and affinity for the agonist accounts for the greater contractile response to Ang II in blood vessels from hypercholesterolemic animals observed in the current and other studies.³⁶

Direct evidence for increased AT₁ receptor expression came from autoradiographic studies in rabbit aortas. We found that Ang II receptor expression was dramatically increased in aortic tissues from hypercholesterolemic rabbits. The increase in Ang II receptor expression was entirely due to an increase in AT₁ expression, because AT₂ expression was unaltered. Nickenig et al⁴⁰ have recently shown that Ang II receptor gene expression is upregulated in rat aortic vascular smooth muscle cells by LDL.

Ang II receptor expression has been demonstrated in the neointima of experimentally injured vessels⁸ and vascular smooth muscle cells of human atherosclerotic plaques.⁶ The critical role of tissue Ang II receptor expression and activation in the pathobiology of intimal hyperplasia is supported by the observation of prevention of neointimal hyperplasia in response to vascular injury and atherosclerosis by ACE inhibitors and AT₁ receptor antagonists.^{10 40 41} The protective effects of the AT₁ receptor antagonists SR 47436 and losartan on Ang II–mediated proliferation of cultured human vascular smooth muscle cells after ischemic injury have been reported.^{42 43} It is noteworthy that the proliferation of vascular smooth muscle cells in these studies was not affected by the AT₂ receptor antagonist PD 123,177.⁴³ Weber et al² showed that Ang II increased mitogenicity, intracellular calcium, phosphoinositol metabolism, and phosphorylation of a specific substrate for protein kinase C in cultured rat aortic smooth muscle cells and that the effect of Ang II was blocked by the AT₁ receptor blocker losartan. Makita et al⁴⁴ showed that AT₁ receptor blockade with losartan blocked Ang II–stimulated as well as basal proliferation of human vascular smooth muscle cells. Collectively, these observations suggest that the AT₁ receptor is expressed in large amounts in atherosclerotic tissues and probably participates in atherogenesis.

Ang II has cellular growth–promoting activity. In vascular smooth muscle cells, Ang II has been shown to activate fibroblast growth factor, platelet-derived growth factor, and transforming growth factor-ß1.^{6 7} The endothelium is an important factor in modulating smooth muscle function and growth, and the presence of normal endothelium has been shown to inhibit Ang II–induced growth-promoting effects.^{45 46} The endothelium-produced vasodilator substances, such as prostacyclin and NO, which have growth-inhibitory actions, help maintain vascular ultrastructure. In conditions associated with diminished synthesis of NO or excessive degradation of NO, the proliferative effect of Ang II is favored, and growth of vascular smooth muscle cells may result.⁴⁷ Recent studies have shown that Ang II via AT₁ receptor activation enhances vascular superoxide formation via membrane NADH/NADPH oxidase activation and contributes to the increase in vascular tone.⁴⁸ Other studies have documented an inhibitory effect of AT₁ receptor activation on NO synthetase mRNA and restoration of mRNA expression and NO-mediated vasorelaxation with blockade of AT₁ receptors.^{49 50} These studies provide a conceptual basis for the relationship between increased AT₁ expression and loss of NO-dependent relaxation in the presence of atherosclerosis.

The autoradiographic technique used in the current study does not permit precise localization of the Ang II receptors in the cytoplasm or the cell membrane. It is known that Ang II receptor sites are located mostly on the vascular smooth muscle cell membrane.⁵¹ Zambetis et al⁵² studied Ang II binding sites in rabbit arteries and found the binding sites to be dispersed throughout the media, with the highest levels of binding in the outer media as well as in the extra-adventitial inflammatory tissue of the atherosclerotic arteries. The immunohistochemical staining with a specific monoclonal antibody to AT₁ receptors in our study indicated that AT₁ receptor expression was predominantly in the media and to a small extent in the intima. Additional evidence from immunohistochemistry with a polyclonal antibody to AT₁ receptors also indicated that the enhanced AT₁ receptor expression was localized primarily in the medial layers of atherosclerotic aortas. It is possible that the immunostaining represented, at least in part, expression of AT₁ receptors in macrophages, monocyte-derived smooth muscle cells, or both.

The monoclonal antibody to the AT₁ receptor expression used in the current study was produced in Professor Vinson's laboratory. This antibody was produced by immunization of BALB/c mice with synthetic peptides representing sequences from the extracellular domain (residues 8 to 17) or the intracellular domain (residues 229 to 237) of the AT₁ receptor. Initial characterization of the antibody showed specific immunofluorescence of vascular endothelium.¹⁹ This group subsequently demonstrated that the monoclonal antibody (6313/G2) to the AT₁ receptor is specifically directed against the N-terminal extracellular domain of the mammalian AT₁ receptor.^{53 54} This monoclonal antibody (6313/G2) to the AT₁ receptor has since been used by other investigators to identify AT₁ receptor expression in brain neurons.^{55 56} The polyclonal antibody was produced in our laboratory after immunization of rats with synthetic peptides, which represent amino acid sequence N-terminal 14–23 residues of the first extracellular domain of the AT₁ receptor and was anchored to the polylysine cores to form the multiple antigenic peptides. The specificity of the antibody was checked by Western blotting. A 65-kDa protein fraction was specifically selected by the antibody. This is the correct molecular weight of the mature, glycosylated AT₁ receptor.²¹

We conducted RT-PCR to assess whether the increased AT₁ expression was due to increased AT₁ receptor mRNA. As shown in Figure 6, we found a marked increase in AT₁ receptor mRNA in aortic tissues of rabbits fed the high-cholesterol diet. In contrast, there was almost no detectable AT₁ receptor mRNA in aortic tissues of rabbits fed the control diet. There is preliminary evidence that ACE levels in atherosclerotic regions of hypercholesterolemic rabbits are significantly reduced,⁵² and it is conceivable that the reduction in tissue Ang II upregulates Ang II receptor expression.

The finding of markedly increased AT₁ receptor expression in arteries from hypercholesterolemic animals is important for understanding the development and potential control of atherosclerotic plaque. A marked increase in AT₁ receptor expression may be the primary basis of an Ang II–mediated increase in smooth muscle cell migration, an effect enhanced by diminished NO release.⁵⁷ Direct demonstration of a severalfold increase in AT₁ expression in the atherosclerotic aortas of rabbits in this study should provide impetus for the use of not only chemical blockade of AT₁ receptors but also of molecular biology–based techniques, such as the development of antisense oligonucleotides and antibodies to AT₁ receptors, to limit atherosclerosis and preserve vascular reactivity.

	Acknowledgments

 
This study was supported in part by a grant from the American Heart Association, Florida Affiliate, St Petersburg, Fla (to B.C.Y.); a Merit Review grant from the Department of Veterans Affairs (to J.L.M.); and a MERIT grant from the National Institutes of Health, Bethesda, Md (to M.I.P.).

Received December 17, 1997; accepted March 24, 1998.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Dzau VJ, Mukoyama M, Pratt RE. Molecular biology of angiotensin receptor: target for drug research? J Hypertens. 1994;12(suppl 2):S1–S5.

2. Weber H, Webb ML, Serafino R, Raylor DS, Moreland S, Norman J, Molloy CJ. Endothelin-1 and angiotensin-II stimulate delayed mitogenesis in cultured rat aortic smooth muscle cells: evidence for common signaling mechanisms. Mol Endocrinol. 1994;8:148–158.[Abstract/Free Full Text]

3. Geisterfer AAT, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res. 1988;62:749–756.[Abstract/Free Full Text]

4. Pratt RE, Itoh H, Gibbons GH, Dzau VJ. Role of angiotensin in the control of vascular smooth muscle cell growth. J Vasc Med Biol. 1991;3:25–29.

5. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell response to angiotensin II. J Clin Invest. 1993;91:2268–2274.

6. Dzau VJ. Cell biology and genetics of angiotensin in cardiovascular disease. J Hypertens. 1994;12(suppl 4):S3–S10.

7. Rakugi H, Kim DK, Krieger JE, Wang DS, Dzau VJ. Induction of angiotensin converting enzyme in the neointima after vascular injury: possible role in restenosis. J Clin Invest. 1994;93:339–346.

8. Viswanathan M, Stromberg C, Seltzer A, Saavedra JM. Balloon angioplasty enhances the expression of angiotensin II AT₁ receptors in neointima of rat aorta. J Clin Invest. 1992;90:1707–1712.

9. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990's. Nature. 1993;362:801–809.[Medline] [Order article via Infotrieve]

10. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1990;15:327–331.[Abstract/Free Full Text]

11. Bocan TM, Mueller SB, Mazur MJ, Uhlendorf PD, Brown EQ, Kieft KA. The relationship between the degree of dietary-induced hypercholesterolemia in the rabbit and atherosclerotic lesion formation. Atherosclerosis. 1993;102:9–22.[Medline] [Order article via Infotrieve]

12. Chen LY, Haught WH, Yang BC, Saldeen TGP, Parathasarathy S, Mehta JL. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of anti-atherosclerotic effect of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol. 1997;30:569–575.[Abstract]

13. Candipan RC, Wang BY, Buitrago R, Tsao PS, Cooke JP. Regression or progression: dependency on vascular nitric oxide. Arterioscler Thromb Vasc Biol.. 1996;16:44–50.[Abstract/Free Full Text]

14. Holman Rl, McGill HC, Strong JP, Geer JC. Technics for studying atherosclerotic lesions. Lab Invest. 1958;7:425–435.

15. Yang BC, Phillips MI, Mehta P, Mehta JL. Increase in angiotensin II type 1 receptor expression immediately following ischemia-reperfusion in isolated rat hearts. Circulation. 1997;96:934–940.[Abstract/Free Full Text]

16. Phillips MI, Wielbo D, Gyurko R. Antisense inhibition of hypertension: a new strategy for renin-angiotensin candidate genes. Kidney Int. 1994;46:1554–1556.[Medline] [Order article via Infotrieve]

17. Wielbo D, Sernia C, Gyurko R, Phillips MI. Antisense inhibition of hypertension in the spontaneously hypertensive rat. Hypertension. 1995;25:314–319.[Abstract/Free Full Text]

18. Yang BC, Nicolini FA, Nichols WW, Mehta JL. Decreased endothelium-dependent vascular relaxation following subtotal coronary artery occlusion in dogs. Free Radic Biol Med. 1993;14:295–302.[Medline] [Order article via Infotrieve]

19. Barker S, Marchant W, Ho MM, Puddefoot JR, Hinson JP, Clark AJ, Vinson GP. A monoclonal antibody to a conserved sequence in the extracellular domain recognizes the angiotensin II AT₁ receptor in mammalian target tissues. J Mol Endocrinol. 1993;11:241–245.[Abstract/Free Full Text]

20. Mehta A, Yang BC, Khan S, Mehta JL. Oxidized low density lipoprotein promotes leukocyte adhesion to vascular intima before attenuation of endothelium-dependent relaxation. Arterioscler Thromb Vasc Biol. 1995;15:2076–2083.[Abstract/Free Full Text]

21. Meng HB, Phillips MI. Autoimmunization against angiotensin type-1 receptor prevents the neointimal proliferation following angioplasty. Hypertension. 1996;28:528. Abstract.

22. Chomczynski PK, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156–159.[Medline] [Order article via Infotrieve]

23. Burns KD, Inagami T, Harris RC. Cloning of a rabbit kidney cortex AT₁ angiotensin II receptor that is present in proximal tubule epithelium. Am J Physiol. 1993;264:F645–F654.[Abstract/Free Full Text]

24. Stamler J, Wentworth D, Neaton J. Is the relationship between serum cholesterol and risk of death from coronary heart disease continuous or graded? JAMA.. 1986;256:2823–2828.[Abstract/Free Full Text]

25. Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Survival Study. Lancet. 1995;345:1274–1275.[Medline] [Order article via Infotrieve]

26. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–1307.[Abstract/Free Full Text]

27. Duffield RG, Lewis B, Miller NE. Treatment of hyperlipidemia retards progression of symptomatic femoral atherosclerosis: a randomized control trial. Lancet. 1983;2:639–642.[Medline] [Order article via Infotrieve]

28. Jessup W, Dean RT. Autoinhibition of murine macrophage-mediated oxidation of low-density lipoprotein by nitric oxide synthesis. Atherosclerosis. 1993;101:145–155.[Medline] [Order article via Infotrieve]

29. Provost P, Lam JY, Lacoste L, Merhi Y, Waters D. Endothelium-derived nitric oxide attenuates neutrophil adhesion to endothelium under arterial flow conditions. Arterioscler Thromb. 1994;14:331–335.[Abstract/Free Full Text]

30. Gary UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83:1774–1777.

31. Mellion BT, Ignarro LJ, Ohlstein EH, Pontecorvo EG, Hyman AL, Kadowitz PJ. Evidence for the inhibitory role of guanosine 3',5'-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood. 1981;57:946–955.[Free Full Text]

32. Mugge A, Forstermann U, Lichtlen PR. Endothelial functions in cardiovascular diseases. Z Kardiol. 1989;78:147–160.[Medline] [Order article via Infotrieve]

33. Harrison DG. Endothelial dysfunction in atherosclerosis. Basic Res Cardiol. 1994;89:87–102.

34. Jayakody L, Kappagoda T, Senaratne MPJ, Thomson ABR. Impairment of endothelium-dependent relaxation: an early marker for atherosclerosis in the rabbit. Br J Pharmacol. 1988;94:335–346.[Medline] [Order article via Infotrieve]

35. Forstermann UA, Mügge A, Acheid A, Haverich A, Frolich JC. Selective attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries. Circ Res. 1988;62:185–190.[Abstract/Free Full Text]

36. Hof RP, Tapparelli C, Weinstein DB. Hemodynamic, antivasoconstrictor, and antiatherosclerotic effects of calcium antagonists in animal models of atherosclerosis. J Cardiovasc Pharmacol. 1990;15:S7–S12.

37. Hu Z-W, Shi X-Y, Okazaki M, Hoffman BB. Angiotensin II induces transcription and expression of ₁-adrenergic receptors in vascular smooth muscle cells. Am J Physiol. 1995;268:H1006–H1014.[Abstract/Free Full Text]

38. Dusting GJ, Hyland R, Hickey H, Makdissi M. Angiotensin-converting enzyme inhibitors reduce neointimal thickening and maintain endothelial nitric oxide function in rabbit carotid arteries. Am J Cardiol. 1995;76:24E–27E.[Medline] [Order article via Infotrieve]

39. Perondi R, Saino A, Tio RA, Pomidossi G, Gregorini L, Alessio P, Morganti A, Zanchetti A, Mancia G. ACE inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease. Circulation. 1996;85:2004–2013.[Abstract/Free Full Text]

40. Nickenig G, Sachinidis A, Michaelson F, Böhm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoproteins in vascular smooth muscle cells. Circulation. 1997;95:473–478.[Abstract/Free Full Text]

41. Powell JS, Clozel JP, Muller RKM, Kuhn H, Hefti F, Hosang M, Baumgartner HR. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science. 1989;245:186–188.[Abstract/Free Full Text]

42. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol. 1990;15(suppl 5):S65–S72.

43. Herbert JM, Delisee C, Dol F, Schaeffer P, Cazaubon C, Nisato D, Chatelain P. Effect of SR 47436, a novel angiotensin II AT₁ receptor antagonist, on human vascular smooth muscle cells in vitro. Eur J Pharmacol. 1994;251:143–150.[Medline] [Order article via Infotrieve]

44. Makita S, Nakamura M, Yoshida H, Hiramori K. Effect of angiotensin II receptor blocker on angiotensin II stimulated DNA synthesis of cultured human aortic smooth muscle cells. Life Sci. 1995;56:PL383–PL388.[Medline] [Order article via Infotrieve]

45. Majesky MW, Daeman MJAP, Schwartz SM. -₁Adrenergic stimulation of platelet-derived growth factor A-chain gene expression in rat aorta. J Biol Chem. 1990;265:1082–1088.[Abstract/Free Full Text]

46. Dzau MA, Gibbons GH. Endothelium and growth factors in vascular remodeling for hypertension. Hypertension. 1991;18(suppl III):III–115–III–121.

47. Daeman MJAP, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res. 1991;68:450–456.[Abstract/Free Full Text]

48. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916–1923.[Medline] [Order article via Infotrieve]

49. Chandler LJ, Kopnisky R, Richards E, Crews FT, Sumners C. Angiotensin decreases inducible nitric oxide synthase expression in rat astroglial cultures. Am J Physiol. 1995;268:C700–C707.[Abstract/Free Full Text]

50. Tschudi MR, Criscione L, Novosel D, Pfeffer K, Luscher TP. Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats. Circulation. 1994;89:2212–2218.[Abstract/Free Full Text]

51. Feolde E, Vigne P, Frelin C. Angiotensin II receptor subtypes and biological response in the rat heart. J Mol Cell Cardiol. 1993;25:1359–1367.[Medline] [Order article via Infotrieve]

52. Zambetis B, Dusting, GJ, Mendelsohn FA, Richardson K. Autoradiographic localization of angiotensin-converting enzyme and angiotensin II binding sites in early atheroma-like lesions in rabbit arteries. Clin Exp Pharmacol Physiol. 1991;18:337–340.[Medline] [Order article via Infotrieve]

53. Vinson GP, Ho MM, Puddefoot JR, Teja R, Barker S. Internalisation of the type 1 angiotensin II receptor (AT1) and angiotensin II function in the rat adrenal zona glomerulosa cell. J Endocrinol. 1994;141:R5–R9.[Abstract/Free Full Text]

54. Villela S, Zinna V, Marsigliante S, Ingrosso L, Muscella A, Ho MM, Vinson GP, Storelli C. Angiotensin II stimulation of the basolateral located Na⁺/K⁺ antiporter in eel (Anguilla anguilla). J Mol Endocrinol. 1996;16:57–62.[Abstract/Free Full Text]

55. Yang H, Lu D, Vinson GP, Raizada MK. Involvement of the MAP kinase in angiotensin II-induced phosphorylation and intracellular targeting of neuronal AT₁ receptors. J Neurosci. 1997;17:1660–1669.[Abstract/Free Full Text]

56. Lu D, Yang H, Shaw G, Raizada MK. Angiotensin II-induced nuclear targeting of the angiotensin type 1 (AT₁) receptor in brain neurons. Endocrinology. 1998;139:365–375.[Abstract/Free Full Text]

57. Dubey RK, Jackson EK, Luscher TF. Nitric oxide inhibits angiotensin II-mediated migration of rat aortic smooth muscle cells. J Clin Invest. 1995;96:141–149.

This article has been cited by other articles:

				R. Cianci, A. Gigante, L. Polidori, D. Di Donato, P. Martina, B. Barbano, R. Renzulli, A. Zaccaria, and G. Fuiano In-Stent Restenosis of the Renal Artery in a Single Kidney Patient: The Role of ACEI in the Therapeutic Choice Angiology, August 1, 2009; 60(4): 496 - 503. [Abstract] [PDF]

				A. Tavridou, L. Kaklamanis, A. Papalois, A. P. Kourounakis, E. A. Rekka, P. N. Kourounakis, A. Charalambous, and V. G. Manolopoulos EP2306 [2-(4-Biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol, hydrobromide], A Novel Squalene Synthase Inhibitor, Reduces Atherosclerosis in the Cholesterol-Fed Rabbit J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 794 - 804. [Abstract] [Full Text] [PDF]

				P. K. Mehta and K. K. Griendling Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system Am J Physiol Cell Physiol, January 1, 2007; 292(1): C82 - C97. [Abstract] [Full Text] [PDF]

				N. A.J. van der Linde, E. J.G. Sijbrands, F. Boomsma, and A. H. van den Meiracker Effect of Low-Density Lipoprotein Cholesterol on Angiotensin II Sensitivity: A Randomized Trial With Fluvastatin Hypertension, June 1, 2006; 47(6): 1125 - 1130. [Abstract] [Full Text] [PDF]

				M. Maczewski, M. Borys, P. Kacprzak, T. Gdowski, and D. Wojciechowski Angiotensin II AT1 receptor density on blood platelets predicts early left ventricular remodelling in non-reperfused acute myocardial infarction in humans Eur J Heart Fail, March 1, 2006; 8(2): 173 - 178. [Abstract] [Full Text] [PDF]

				A. A Voors, P. P. van Geel, H. Buikema, M. Oosterga, D. J van Veldhuisen, and W. H van Gilst High Angiotensin II Responsiveness is Associated with Decreased Endothelium-Dependent Relaxation in Human Arteries Journal of Renin-Angiotensin-Aldosterone System, September 1, 2005; 6(3): 145 - 150. [Abstract] [PDF]

				J.L. Mehta, J. Chen, F. Yu, and D.Y. Li Aspirin inhibits ox-LDL-mediated LOX-1 expression and metalloproteinase-1 in human coronary endothelial cells Cardiovasc Res, November 1, 2004; 64(2): 243 - 249. [Abstract] [Full Text] [PDF]

				M. T. Johnstone, A. S. Perez, I. Nasser, R. Stewart, A. Vaidya, F. Al Ammary, B. Schmidt, G. Horowitz, J. Dolgoff, J. Hamilton, et al. Angiotensin Receptor Blockade With Candesartan Attenuates Atherosclerosis, Plaque Disruption, and Macrophage Accumulation Within the Plaque in a Rabbit Model Circulation, October 5, 2004; 110(14): 2060 - 2065. [Abstract] [Full Text] [PDF]

				P. M Ridker, N. J. Brown, D. E. Vaughan, D. G. Harrison, and J. L. Mehta Established and Emerging Plasma Biomarkers in the Prediction of First Atherothrombotic Events Circulation, June 29, 2004; 109(25_suppl_1): IV-6 - IV-19. [Full Text] [PDF]

				K. A. Buhagiar, P. S. Hansen, B. Y. Kong, R. J. Clarke, C. Fernandes, and H. H. Rasmussen Dietary cholesterol alters Na+/K+ selectivity at intracellular Na+/K+ pump sites in cardiac myocytes Am J Physiol Cell Physiol, February 1, 2004; 286(2): C398 - C405. [Abstract] [Full Text]

				J. L. Mehta, B. Hu, J. Chen, and D. Li Pioglitazone Inhibits LOX-1 Expression in Human Coronary Artery Endothelial Cells by Reducing Intracellular Superoxide Radical Generation Arterioscler Thromb Vasc Biol, December 1, 2003; 23(12): 2203 - 2208. [Abstract] [Full Text] [PDF]

				H. Eto, S. Biro, M. Miyata, H. Kaieda, H. Obata, T. Kihara, K. Orihara, and C. Tei Angiotensin II type 1 receptor participates in extracellular matrix production in the late stage of remodeling after vascular injury Cardiovasc Res, July 1, 2003; 59(1): 200 - 211. [Abstract] [Full Text] [PDF]

				B. D. Wyse, I. A. Prior, H. Qian, I. C. Morrow, S. Nixon, C. Muncke, T. V. Kurzchalia, W. G. Thomas, R. G. Parton, and J. F. Hancock Caveolin Interacts with the Angiotensin II Type 1 Receptor during Exocytic Transport but Not at the Plasma Membrane J. Biol. Chem., June 20, 2003; 278(26): 23738 - 23746. [Abstract] [Full Text] [PDF]

				B. M. Singh and J. L. Mehta Interactions Between the Renin-Angiotensin System and Dyslipidemia: Relevance in the Therapy of Hypertension and Coronary Heart Disease Arch Intern Med, June 9, 2003; 163(11): 1296 - 1304. [Abstract] [Full Text] [PDF]

				D. Li, V. Williams, L. Liu, H. Chen, T. Sawamura, F. Romeo, and J. L. Mehta Expression of lectin-like oxidized low-density lipoprotein receptors during ischemia-reperfusion and its role in determination of apoptosis and left ventricular dysfunction J. Am. Coll. Cardiol., March 19, 2003; 41(6): 1048 - 1055. [Abstract] [Full Text] [PDF]

				C. Yan, D. Kim, T. Aizawa, and B. C. Berk Functional Interplay Between Angiotensin II and Nitric Oxide: Cyclic GMP as a Key Mediator Arterioscler Thromb Vasc Biol, January 1, 2003; 23(1): 26 - 36. [Abstract] [Full Text] [PDF]

				D. Li, V. Williams, L. Liu, H. Chen, T. Sawamura, T. Antakli, and J. L. Mehta LOX-1 inhibition in myocardial ischemia-reperfusion injury: modulation of MMP-1 and inflammation Am J Physiol Heart Circ Physiol, November 1, 2002; 283(5): H1795 - H1801. [Abstract] [Full Text] [PDF]

				Y. Uehara, H. Urata, M. Ideishi, K. Arakawa, and K. Saku Chymase inhibition suppresses high-cholesterol diet-induced lipid accumulation in the hamster aorta Cardiovasc Res, September 1, 2002; 55(4): 870 - 876. [Abstract] [Full Text] [PDF]

				J. L. Mehta and D. Li Identification, regulation and function of a novel lectin-like oxidized low-density lipoprotein receptor J. Am. Coll. Cardiol., May 1, 2002; 39(9): 1429 - 1435. [Abstract] [Full Text] [PDF]

				S. Keidar, R. Heinrich, M. Kaplan, and M. Aviram Oxidative stress increases the expression of the angiotensin-II receptor type 1 in mouse peritoneal macrophages Journal of Renin-Angiotensin-Aldosterone System, March 1, 2002; 3(1): 24 - 30. [Abstract] [PDF]

				E. A. Jaimes, C. Sweeney, and L. Raij Effects of the Reactive Oxygen Species Hydrogen Peroxide and Hypochlorite on Endothelial Nitric Oxide Production Hypertension, October 1, 2001; 38(4): 877 - 883. [Abstract] [Full Text] [PDF]

				J. L Mehta and Dayuan Li Facilitative interaction between angiotensin II and oxidised LDL in cultured human coronary artery endothelial cells Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S70 - S76. [Abstract] [PDF]

				D. Li, T. Saldeen, F. Romeo, and J. L. Mehta Oxidized LDL Upregulates Angiotensin II Type 1 Receptor Expression in Cultured Human Coronary Artery Endothelial Cells : The Potential Role of Transcription Factor NF-{kappa}B Circulation, October 17, 2000; 102(16): 1970 - 1976. [Abstract] [Full Text] [PDF]

				W. B. Strawn, M. C. Chappell, R. H. Dean, S. Kivlighn, and C. M. Ferrario Inhibition of Early Atherogenesis by Losartan in Monkeys With Diet-Induced Hypercholesterolemia Circulation, April 4, 2000; 101(13): 1586 - 1593. [Abstract] [Full Text] [PDF]

				M. Schachter ACE inhibitors, angiotensin receptor antagonists and bradykinin Journal of Renin-Angiotensin-Aldosterone System, March 1, 2000; 1(1): 27 - 29. [PDF]

				S. Kim and H. Iwao Molecular and Cellular Mechanisms of Angiotensin II-Mediated Cardiovascular and Renal Diseases Pharmacol. Rev., March 1, 2000; 52(1): 11 - 34. [Abstract] [Full Text] [PDF]

				K. Wilfert, K. Drischel, A. Unbehaun, H. Guski, P. B. Persson, and H. M. Stauss Vascular Response to Angiotensin II in Atherosclerosis : Role of the Baroreflex Hypertension, February 1, 2000; 35(2): 685 - 690. [Abstract] [Full Text] [PDF]

				S. Rajagopalan, D. Duquaine, S. King, B. Pitt, and P. Patel Mineralocorticoid Receptor Antagonism in Experimental Atherosclerosis Circulation, May 7, 2002; 105(18): 2212 - 2216. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yang, B. C. Articles by Mehta, J. L. Search for Related Content PubMed PubMed Citation Articles by Yang, B. C. Articles by Mehta, J. L. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Cholesterol